Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer

Lung cancer has recently been discovered to be an immunological targetable disease, on the basis of the exciting results of the randomized trials with immune checkpoint inhibitors. Nevertheless, the survival benefit appears to not be entirely captured by the usual outcome measures, thus requiring a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Transl Lung Cancer Res
Autori principali: Pilotto, Sara, Carbognin, Luisa, Karachaliou, Niki, Garassino, Marina, Cuppone, Federica, Petraglia, Sandra, Rosell, Rafael, Tortora, Giampaolo, Bria, Emilio
Natura: Artigo
Lingua:Inglês
Pubblicazione: AME Publishing Company 2015
Soggetti:
Review Article on Lung Cancer Immunotherapy
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4700216/
https://ncbi.nlm.nih.gov/pubmed/26798579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.10.08
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi